APRE
Aprea Therapeutics, Inc.
$0.7340
-0.94%
$9.1M
No data for this timeframe.
Vol
Market Cap$9.1M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders3 funds
Inst. Value$118.1K
Inst. Activity0 buys / 2 sells
Insider Activity8B / 0S
Insider Net $$155.1K
Reddit Sentiment50° Neutral
SEC Reports7
Press Releases2
Recent Activity
May 13, 2026
SEC
Aprea Therapeutics reported Q1 2026 results with a net loss of $3.3M ($0.22/share), narrower than the $3.9M loss in Q1 2
8-K — Impact 7/10
May 13, 2026
SEC
Aprea Therapeutics reported Q1 2026 EPS of -$0.22 (GAAP), beating the -$0.23 consensus by 4.3%, but the headline EPS mis
PRESS-RELEASE — Impact 5/10
May 13, 2026
earnings
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
<p>DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Apr
Apr 30, 2026
SEC
Aprea Therapeutics filed a DEFA14A providing notice of its 2026 Annual Meeting, including proposals to elect three Class
DEFA14A — Impact 7/10
Mar 31, 2026
Insider
Peters Richard bought 123,915 shares
Director @ $0.00 ($0.00)
Mar 31, 2026
Insider
Peters Richard bought 123,915 shares
Director @ $0.8070 ($100.0K)
Mar 31, 2026
Insider
Hamill John P. bought 30,978 shares
SrVP/CFO/Prin Fin & Acct Ofcr @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — TRIM
58,086 shares ($49.5K)
Price Targets
$4.30
+482.3% upside
Strong Buy
Current $0.7385
Low $1.20
Median $5.00
High $6.00
4 analysts
$1.20
$6.00
Analyst Ratings
4Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 7, 2026 | Oppenheimer | INITIATE | Outperform |
| Mar 31, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Feb 10, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.22 | $-0.23 — $-0.21 | 58% YoY | 2 |
| Next Q | $-0.23 | $-0.24 — $-0.23 | 50% YoY | 2 |
| Current FY | $-0.83 | $-0.93 — $-0.66 | 57% YoY | 3 |
| Next FY | $-0.79 | $-1.05 — $-0.42 | 5% YoY | 3 |
Latest Reports
BULLISH
8-K
7/10
Aprea Therapeutics reported Q1 2026 results with a net loss of $3.3M ($0.22/share), narrower than the $3.9M loss in Q1 2
May 13, 2026
NEUTRAL
PRESS-RELEASE
5/10
Aprea Therapeutics reported Q1 2026 EPS of -$0.22 (GAAP), beating the -$0.23 consensus by 4.3%, but the headline EPS mis
May 13, 2026
BULLISH
Press
7/10
Aprea Therapeutics announced that early results from the first-in-human Phase 1 trial of its WEE1 inhibitor APR-1051 wil
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $65.7K | ADD |
| VANGUARD GROUP INC | $49.5K | TRIM |
| BANK OF AMERICA CORP | $2.8K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | Peters Richard | BUY | $0.00 |
| Mar 31, 2026 | Peters Richard | BUY | $100.0K |
| Mar 31, 2026 | Hamill John | BUY | $0.00 |
| Mar 31, 2026 | Hamill John | BUY | $25.0K |
| Mar 12, 2026 | Hamill John | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
3 institutional holders with $118.1K total value (138,415 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, BANK. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 77,030 | $65.7K | 55.7% | ADD +93.0% |
| 2 | VANGUARD GROUP INC | 58,086 | $49.5K | 42.0% | TRIM -63.3% |
| 3 | BANK OF AMERICA CORP /DE/ | 3,299 | $2.8K | 2.4% | TRIM -32.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | TRIM | 158,238 | 58,086 | -63.3% | $49.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 4,861 | 3,299 | -32.1% | $2.8K | 2025-Q4 |
| UBS Group AG | TRIM | 8 | 3 | -62.5% | $4.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 32,808 | 63,331 | +93.0% | $107.0K | 2025-Q2 |
| UBS Group AG | DOUBLED | 3 | 8 | +166.7% | $13.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 30,083 | — | $61.4K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 5,935 | 3 | -99.9% | $6.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 3 | 5,935 | +197733.3% | $19.5K | 2024-Q4 |
3 unique insiders with 8 transactions. Net insider value: $155.1K ($155.1K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Peters Richard | Director | BUY | 123,915 | $0.00 | $0.00 |
| Mar 31, 2026 | Peters Richard | Director | BUY | 123,915 | $0.8070 | $100.0K |
| Mar 31, 2026 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | BUY | 30,978 | $0.00 | $0.00 |
| Mar 31, 2026 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | BUY | 30,978 | $0.8070 | $25.0K |
| Mar 12, 2026 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | A | 10,095 | $0.00 | $0.00 |
| Mar 12, 2026 | Gilad Oren | President/CEO | A | 80,700 | $0.00 | $0.00 |
| Mar 12, 2026 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | A | 40,380 | $0.00 | $0.00 |
| Mar 12, 2026 | Gilad Oren | President/CEO | A | 20,175 | $0.00 | $0.00 |
| Jan 30, 2026 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | BUY | 5,700 | $0.8900 | $5.1K |
| Jan 30, 2026 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | BUY | 5,700 | $0.00 | $0.00 |
| Jan 30, 2026 | Gilad Oren | President/CEO | BUY | 28,100 | $0.8900 | $25.0K |
| Jan 30, 2026 | Gilad Oren | President/CEO | BUY | 28,100 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 3 bearish, 0 mixed, 2 neutral. Avg impact: 5.7/10.
BULLISH
8-K
7/10
Aprea Therapeutics reported Q1 2026 results with a net loss of $3.3M ($0.22/share), narrower than th
May 13, 2026
NEUTRAL
PRESS-RELEASE
5/10
Aprea Therapeutics reported Q1 2026 EPS of -$0.22 (GAAP), beating the -$0.23 consensus by 4.3%, but
May 13, 2026
BEARISH
DEFA14A
7/10
Aprea Therapeutics filed a DEFA14A providing notice of its 2026 Annual Meeting, including proposals
Apr 30, 2026
BEARISH
S-3
7/10
Aprea Therapeutics filed an S-3 shelf registration to allow resale of 74.3 million shares by selling
Apr 22, 2026
BULLISH
CLUSTER
6/10
Two corporate insiders at Aprea Therapeutics — CFO John Hamill and Director Richard Peters — collect
Apr 1, 2026
NEUTRAL
EFFECT
4/10
Aprea Therapeutics' shelf registration (Form S-3) has become effective, allowing the company to issu
Mar 20, 2026
BEARISH
S-3/A
4/10
Aprea Therapeutics filed an S-3/A amendment solely to update the auditor's consent from EisnerAmper.
Mar 17, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 4 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.30 mean target
+482.3% upside
Strong Buy (3.00)
$1.20 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $0.7385 |
| Target Low | $1.20 |
| Target Mean | $4.30 |
| Target Median | $5.00 |
| Target High | $6.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.22 | $-0.23 | $-0.21 | 58.5% | — | — | $0.0B | 7.1% | 2 |
| Next Q 2026-09-30 |
$-0.23 | $-0.24 | $-0.23 | 50.0% | — | — | $0.0B | 8210.8% | 2 |
| Current FY 2026-12-31 |
$-0.83 | $-0.93 | $-0.66 | 57.0% | — | 1↑ 0↓ | $0.0B | 87.2% | 3 |
| Next FY 2027-12-31 |
$-0.79 | $-1.05 | $-0.42 | 4.8% | — | — | $0.0B | 111.5% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.220 | |
| 7d ago | $-0.235 | +0.015 |
| 30d ago | $0.000 | -0.220 |
| 60d ago | $0.000 | -0.220 |
| 90d ago | $0.000 | -0.220 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Mar 31, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
1 bullish
1 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Trying to figure out the best penny stocks to buy now
▲ 1
💬 1
⚡ 0.5
Insider Buys/Sells - AI Slop Scan
▲ 7
💬 2
⚡ 0.0
May 13, 2026
earnings
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
<p>DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision
May 13, 2026
earnings_calendar
APRE Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings_calendar
APRE Q1 2026 Earnings Scheduled — 2026-05-12
May 8, 2026
short_volume
Short Volume: APRE — 59.5% short (0.3M / 0.6M)
Short: 338,470 | Exempt: 0 | TRF Vol: 569,147 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
fda
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
<p align="left">DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-
Mar 30, 2026
offering
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
<p align="justify">DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinic
Mar 30, 2026
short_volume
Short Volume: APRE — 56.6% short (0.7M / 1.3M)
Short: 727,860 | Exempt: 41,188 | TRF Vol: 1,286,935 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
earnings_calendar
APRE Q4 2025 Earnings After Market Close — 2026-03-23
Mar 16, 2026
earnings
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
<p>DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precisi